What Gelmetix does

Gelmetix is a UK-based medical device company founded in 2012 as a spin-out from the University of Manchester, developing injectable polymer hydrogel treatments for chronic lower-back pain caused by degenerative disc disease. Its lead product, DXM (Disc eXtra Matrix), is a pH-responsive, double cross-linked hydrogel designed to be injected into the nucleus pulposus to restore water content, rehydrate the disc, and maintain disc height, addressing the mechano-biological root cause of pain rather than masking symptoms. A second product, SXM, is in pre-clinical development and extends the same polymer platform to provide viscosity and lubrication for small joints, facet joints of the spine, and potentially larger joints.

The company's core technology is a patented polymer gel platform originating from over 25 years of academic research by co-founders Tony Freemont (Osteoarticular Pathology) and Brian Saunders (Polymer and Colloid Chemistry) at the University of Manchester, supported by peer-reviewed publications in materials science and clinical journals. DXM is positioned as a Class III medical device to be administered by discography-trained spine care specialists (spine surgeons, interventional radiologists, neurologists, rheumatologists) as a minimally invasive, ambulant procedure under local anesthetic, filling the treatment gap between conservative therapy and surgery.

Gelmetix is pre-revenue. Its near-term economics are driven by clinical advancement and capital raises rather than product sales; ~$14.75M has been disclosed across four funding rounds since 2014, with investors including Seneca Partners, The North West Fund, Fund Twenty8, Wealth Club, Spark Impact, and the University of Manchester. The future revenue model is expected to combine direct medical device sales to hospitals and specialty spine clinics with potential platform licensing for additional indications and for use as a carrier for regenerative agents such as anti-inflammatories or stem cells. The company is led by CEO Andy Weymann MD (former Smith+Nephew CMO) and maintains a board with deep orthopedic and medical device commercial experience.

Name

Gelmetix

Legal name

Gelmetix

Website

https://gelmetix.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Gelmetix is a UK medical device company developing injectable pH-responsive hydrogel treatments, led by DXM for chronic lower-back pain from degenerative disc disease, with a follow-on SXM program for joint indications, sold to spine specialists once approved.

Ownership category

akta.pro rank

Product category

Spinal Medical Devices

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC)

akta.pro secondary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Disc rehydration therapy
• Hydrogel medical device
• Degenerative disc treatment
• Minimally invasive spine
• Polymer gel technology

Headquarters

HQ city

Macclesfield

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Product Sales: Once DXM receives regulatory approval, the company plans to commercialize its hydrogel products for treating degenerative disc disease. As a Class III medical device requiring injection by trained physicians, the revenue model will likely involve direct sales to hospitals and specialty spine clinics, with potential for outpatient procedure-based billing.
2. Platform Technology Licensing: The patented polymer gel technology platform has potential for adaptation and extension for other uses including viscosity and lubrication for small joints, facet joints of the spine, and larger joints. The gels may also act as carriers for regenerative agents such as anti-inflammatories or stem cells, creating licensing opportunities.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Gelmetix develops and intends to commercialize DXM (Disc eXtra Matrix), a pH-responsive, double cross-linked hydrogel injected under image guidance into degenerated lumbar intervertebral discs. The hydrogel restores nucleus pulposus water content and disc height, relieving chronic low-back pain through a minimally invasive, single-injection procedure performed by spine care physicians. A second pipeline product, SXM, is in pre-clinical development for joint lubrication and viscosity applications.

Product overview

Gelmetix is a medical technology company offering a patented polymer gel technology platform for treating chronic low-back pain and degenerative joint conditions. The company's primary product is DXM (Disc eXtra Matrix), a pH-responsive, double cross-linked hydrogel that provides disc rehydration therapy for degenerative disc disease. A second product, SXM, is in pre-clinical development. Both products leverage the company's core polymer gel technology platform, which can act as a carrier for regenerative agents and be adapted for multiple indications including small joints, facet joints, and larger joints throughout the body.

Differentiator

Problem solved

Functional benefit

Products and services

• DXM (Disc eXtra Matrix) A pH-responsive, double cross-linked hydrogel injected under image guidance into degenerated lumbar intervertebral discs. It restores water content of the nucleus pulposus, re-establishes disc height and hydrostatic pressure, and provides sustained chronic low-back pain relief through a single minimally invasive procedure under local anaesthetic. Indicated for skeletally mature patients with confirmed degenerative disc disease and at least 3 months of prior non-operative treatment. Administered by trained interventional spine specialists (spine surgeons, interventional radiologists, neurologists, rheumatologists).
• SXM A second hydrogel product built on Gelmetix's polymer gel platform, in pre-clinical development, designed to provide viscosity and lubrication to small joints, facet joints of the spine, and potentially larger joints throughout the body.

Quantifiable outcome

• Sustained pain relief following single injection procedure
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• University of ManchestercoreStrategic or Co-development Partner · 1 January 2012University of Manchester spin-out founded in 2012. Technology originated from over 25 years of work by Tony Freemont (Professor of Osteoarticular Pathology) and Brian Saunders (Professor of Polymer and Colloid Chemistry). Prof. Tony Freemont serves as Co-Founder and Director.
• EIT HealthflagshipStrategic or Co-development PartnerEIT Health Catapult program recognition in December 2020. Named 'one of the most promising biotech start-ups in Europe', providing validation and potential network benefits for the company.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• ReGelTec: Develops HYDRAFIL, an injectable hydrogel nucleus replacement for degenerative disc disease. Direct therapeutic and mechanistic analogue to Gelmetix's DXM, targeting the same patient population with a minimally invasive percutaneous injection.
• DiscGenics: Clinical-stage regenerative medicine company developing IDCT (injectable disc cell therapy) for degenerative disc disease. Targets the same lumbar indication as DXM via a percutaneous, image-guided procedure, competing for the same physician and patient pool.
• Mesoblast: Developing MPC-06-ID, an allogeneic mesenchymal stem cell therapy for chronic low-back pain due to degenerative disc disease. Closest large-cap public peer in the same indication, validating market demand and shaping the competitive landscape for DXM.

Emerging players

• Spine BioPharma: Clinical-stage company developing SB-01, an injectable therapeutic for chronic low-back pain associated with degenerative disc disease. Overlaps with DXM in mechanism (injectable, disease-modifying) and physician channel (interventional pain specialists).
• Cerapedics: Commercial-stage company focused on bone graft substitutes for spine surgery, including i-FACTOR Peptide Enhanced Bone Graft. Operates in adjacent spine biologics space with similar physician call points (spine surgeons) and biologics regulatory pathway.

Broad incumbents

• Globus Medical: Major spine hardware and enabling technology company (merged with NuVasive). Broad incumbent offering surgical solutions for degenerative disc disease; competes with DXM by anchoring the surgical treatment arm of the same care continuum.
• Medtronic (Spine & Biologics): Largest spine medtech player with broad portfolio of surgical, biologics, and pain stimulation solutions for degenerative disc disease. Sets the standard of care and reimbursement environment against which DXM will be evaluated.
• Stryker (Spine): Broad orthopedics and spine incumbent with disc replacement and surgical solutions for degenerative spine conditions. Comparable commercial reach and physician relationships in spine care that DXM will need to access or partner around.
• Smith+Nephew: Global medical device incumbent with significant orthopedics franchise. Relevant as Gelmetix CEO Andy Weymann MD is a former CMO of Smith+Nephew, and the company represents a potential strategic acquirer with established spine/orthopedic channels.
• Orthofix Medical: Spine and orthopedics company with motion preservation and biologic solutions for degenerative conditions. Comparable spine-focused medtech with overlapping physician call points and parallel regulatory/commercial pathway considerations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/gelmetix

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gelmetix